PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry – FDA

Опубликовано 3 октября, 201817 декабря, 2018 frozencat

Обновление руководства FDA:

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry

Руководство замещает Adaptive Design Clinical Trials for Drugs and Biologics – 2010.

Рубрики: Блог

Навигация по записям

Предыдущая запись: Определение объема выборки для исследований биоэквивалентности с использованием компьютерного моделирования
Следующая запись: Работа с данными в IBM SPSS: присвоение меток переменным из другого источника

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20180202 170838(0)
DJI 0007
DJI 0014
IMG-20170807-WA0030
DJI 0009
DJI 0007
  • Procedural advice for vaccine platform technology master file (vPTMF) certification
    Source: EMA - Scientific guidelines (human and veterinary) Published on 2025-11-28
  • Guidance for stepwise PIPs (sPIPs)
    Source: EMA - Regulatory and procedural guidelines (human and veterinary) Published on 2025-11-28
  • QE3 Guideline for Extractables and Leachables: Supporting Documentation: Class 3 Leachable Monographs
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-28 By FDA
  • Q3E Guideline for Extractables and Leachables
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-28 By FDA
  • Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine, Date of authorisation: 21/12/2020, Revision: 57, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-28
  • Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine, Date of authorisation: 06/01/2021, Revision: 60, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-28
  • Human medicines European public assessment report (EPAR): MenQuadfi, meningococcal group A, C, W-135 and Y conjugate vaccine, Date of authorisation: 18/11/2020, Revision: 24, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-28
  • Human medicines European public assessment report (EPAR): Kyprolis, carfilzomib, Date of authorisation: 19/11/2015, Revision: 21, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-28
  • Newly Added Guidance Documents
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-28 By FDA
  • Current Good Manufacturing Practice for Medical Gases
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-28 By FDA
  • Human medicines European public assessment report (EPAR): Bilprevda, denosumab, Date of authorisation: 17/09/2025, Revision: 1, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-28
  • PDUFA VIII: Fiscal Years 2028 – 2032
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-28 By FDA
  • Human medicines European public assessment report (EPAR): Atropine sulfate FGK, atropine, Date of refusal: 21/11/2025, Status: Refused
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-28
  • Human medicines European public assessment report (EPAR): Talvey, talquetamab, Date of authorisation: 21/08/2023, Revision: 8, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-28
  • Human medicines European public assessment report (EPAR): Byfavo, remimazolam, Date of authorisation: 26/03/2021, Revision: 9, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-28
Предыдущие записи
Тема: Scaffold от Danny Cooper.